Brad Shapiro
Biographic Data
| ID | 7448695 |
|---|---|
| NAME | Brad Shapiro |
| GIVEN NAMES | Brad |
| FAMILY NAME | Shapiro |
| SIGNATURE | SHAPIRO B |
| AFFILIATIONS | University of California, San Francisco |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2016 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Improving Reproductive Health Communication Between Providers and Women Affected by Homelessness and Substance Use in San Francisco: Results from a Community-Informed Workshop
A half-day workshop increased provider empathy and improved provider confidence in reproductive health counseling of women affected by homelessness and substance use
Get in and get out, get on with life”: Patient and provider perspectives on methadone van implementation for opioid use disorder treatment
Eased restrictions on methadone van implementation represent a new strategy for expanding OUD treatment access. In our qualitative study, patients and staff were satisfied with methadone van implementation, though the OTP still faced implementation challenges. Audio-only counseling and other workflow solutions helped facilitate implementation, and several policy considerations like maintaining audio-only counseling flexibilities are key to ensuri…
A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder
30-60% of patients receiving methadone for opioid use disorder (OUD) actively use cocaine. Cocaine use disorder (CUD) has no FDA-approved pharmacological treatment; existing psychosocial treatments are inadequate. Oxytocin, a social neuropeptide, has preclinical promise as an adjunctive treatment for both OUD and CUD. Twenty-two individuals receiving methadone for OUD with co-occurring CUD were randomized to receive oxytocin or placebo intranasal…
No prominent works on this page.
A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder
30-60% of patients receiving methadone for opioid use disorder (OUD) actively use cocaine. Cocaine use disorder (CUD) has no FDA-approved pharmacological treatment; existing psychosocial treatments are inadequate. Oxytocin, a social neuropeptide, has preclinical promise as an adjunctive treatment for both OUD and CUD. Twenty-two individuals receiving methadone for OUD with co-occurring CUD were randomized to receive oxytocin or placebo intranasal…
Improving Reproductive Health Communication Between Providers and Women Affected by Homelessness and Substance Use in San Francisco: Results from a Community-Informed Workshop
A half-day workshop increased provider empathy and improved provider confidence in reproductive health counseling of women affected by homelessness and substance use
Get in and get out, get on with life”: Patient and provider perspectives on methadone van implementation for opioid use disorder treatment
Eased restrictions on methadone van implementation represent a new strategy for expanding OUD treatment access. In our qualitative study, patients and staff were satisfied with methadone van implementation, though the OTP still faced implementation challenges. Audio-only counseling and other workflow solutions helped facilitate implementation, and several policy considerations like maintaining audio-only counseling flexibilities are key to ensuri…
Medicine (3 works) · Psychiatry (3 works) · Buprenorphine (2 works) · Family medicine (2 works) · Methadone (2 works) · Methadone maintenance (2 works) · Nursing (2 works) · Opiate Substitution Treatment (2 works) · Opioid (2 works) · Opioid use disorder (2 works)